Baltimore, MD, United States
Baltimore, MD, United States

Time filter

Source Type

North America is estimated to hold a whopping 45.3% value share in the global GMP cell banking services market by the end of 2017 and will witness an increase of 231 basis points in market share by 2025 over 2017. The North America regional market will create absolute $ opportunity of US$ 23 Mn in 2018 over 2017. In a new report titled "Global Market Study on GMP Cell Banking Services: Mammalian Cell Type Segment Revenue Projected to Grow 3.2x by 2025 End as Compared to that in 2017," Persistence Market Research forecasts revenue from the North America market to grow 3.1x by 2025 end as compared to that in 2017. This will directly impact the global GMP cell banking services market, which will likely grow from US$ 346.6 Mn in 2017 to US$ 1,012.4 Mn by the end of 2025, translating into a CAGR of 14.3% during the eight year forecast period 2017 - 2025. Strategic industry consolidations and increase in demand for Ready-to-Use (RTU) Bioassay Banks is trending the global GMP cell banking services market One of the key objectives of the report is to identify the key trends governing the global GMP cell banking services market and present a clear picture of the various forces impacting the market at a micro and macro level. A sustained growth of the market can be attributed to macro-economic drivers such as increased public and private sector funding for disease research, which is expected to bring newer therapies to the market; high costs of clinical development; and various collaborative initiatives to identify therapies for difficult-to-treat illnesses. On the supply side, an expansion of production facilities by key players to meet growing customer demand besides offering customized solutions based on specific customer needs (this involves strategic tie-ups between biopharmaceutical companies and cell banking service providers) are some of the factors likely to push the global GMP cell banking services market ahead in the coming years. The report also identifies certain demand side drivers boosting the market such as a growing number of biologics in development currently, limited in-house storage and testing capabilities and a rise in the demand for outsourcing and contract manufacturing. While the above growth factors are indicative of a mature market, Persistence Market Research identifies certain pull factors likely to restrain the market to a certain extent in the coming years. First off, the global GMP cell banking services market is highly fragmented with multiple vendors offering a variety of services - resulting in limited global reach. Besides, complexities in the production and manufacturing processes, a constantly evolving technology landscape, and inconsistent demand for services are likely to restrain revenue growth of the global GMP cell banking services market during the forecast period. Persistence Market Research predicts a large opportunity for key players in the fast growing Asia Pacific region. It must be noted that there has been a shift of R&D and technology investments in the healthcare industry from North America and Europe to Asia Pacific with developing APAC economies such as India offering increased scope for outsourcing of biotech projects owing to ample skilled and qualified manpower at optimal costs. A sample of this report is available upon request@ http://www.persistencemarketresearch.com/samples/13735 Mammalian cell type segment to retain its pole position throughout the forecast period Among the cell type segments, the Mammalian segment was the dominant segment in 2016 and is expected to retain its dominance through 2025. From an estimated US$ 216 Mn in 2017 to a market valuation in excess of US$ 680 Mn by the end of the forecast period, the Mammalian segment will register the highest CAGR of 15.6% among the other cell type segments. The Microbial segment is the second most attractive cell type segment in the global GMP cell banking services market in terms of revenue. Registering a value CAGR of 12.9% between 2017 and 2025, the Microbial segment will hold the second position among the cell type segments of the global GMP cell banking services market. Biopharmaceutical Companies will be the largest end users of GMP cell banking services Among the end user segment of the global GMP cell banking services market, the Biopharmaceutical Companies segment will emerge the undisputed leader both in terms of market share (estimated to hold almost 69% share by 2017 end) and CAGR (an impressive 15.4% during 2017 - 2025). In comparison, the Contract Manufacturing Organizations segment will come a pale second, recording a market attractiveness index of 0.5 during the forecast period. Request to View Report Table of Contents, Figures, and Tables @ http://www.persistencemarketresearch.com/market-research/gmp-cell-banking-service-market/toc The top companies profiled in the report include Wuxi AppTec, Charles River Laboratories International Inc, Eurofins Scientific, Merck KGaA, Lonza Group Ltd., SGS Ltd., ViruSure GmbH, Austrianova, Goodwin Biotechnology Inc., and Paragon Bioservices Inc. Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


North America is estimated to hold a whopping 45.3% value share in the global GMP cell banking services market by the end of 2017 and will witness an increase of 231 basis points in market share by 2025 over 2017. The North America regional market will create absolute $ opportunity of US$ 23 Mn in 2018 over 2017. In a new report titled "Global Market Study on GMP Cell Banking Services: Mammalian Cell Type Segment Revenue Projected to Grow 3.2x by 2025 End as Compared to that in 2017," Persistence Market Research forecasts revenue from the North America market to grow 3.1x by 2025 end as compared to that in 2017. This will directly impact the global GMP cell banking services market, which will likely grow from US$ 346.6 Mn in 2017 to US$ 1,012.4 Mn by the end of 2025, translating into a CAGR of 14.3% during the eight year forecast period 2017 - 2025. Strategic industry consolidations and increase in demand for Ready-to-Use (RTU) Bioassay Banks is trending the global GMP cell banking services market One of the key objectives of the report is to identify the key trends governing the global GMP cell banking services market and present a clear picture of the various forces impacting the market at a micro and macro level. A sustained growth of the market can be attributed to macro-economic drivers such as increased public and private sector funding for disease research, which is expected to bring newer therapies to the market; high costs of clinical development; and various collaborative initiatives to identify therapies for difficult-to-treat illnesses. On the supply side, an expansion of production facilities by key players to meet growing customer demand besides offering customized solutions based on specific customer needs (this involves strategic tie-ups between biopharmaceutical companies and cell banking service providers) are some of the factors likely to push the global GMP cell banking services market ahead in the coming years. The report also identifies certain demand side drivers boosting the market such as a growing number of biologics in development currently, limited in-house storage and testing capabilities and a rise in the demand for outsourcing and contract manufacturing. While the above growth factors are indicative of a mature market, Persistence Market Research identifies certain pull factors likely to restrain the market to a certain extent in the coming years. First off, the global GMP cell banking services market is highly fragmented with multiple vendors offering a variety of services - resulting in limited global reach. Besides, complexities in the production and manufacturing processes, a constantly evolving technology landscape, and inconsistent demand for services are likely to restrain revenue growth of the global GMP cell banking services market during the forecast period. Persistence Market Research predicts a large opportunity for key players in the fast growing Asia Pacific region. It must be noted that there has been a shift of R&D and technology investments in the healthcare industry from North America and Europe to Asia Pacific with developing APAC economies such as India offering increased scope for outsourcing of biotech projects owing to ample skilled and qualified manpower at optimal costs. A sample of this report is available upon request@ http://www.persistencemarketresearch.com/samples/13735 Mammalian cell type segment to retain its pole position throughout the forecast period Among the cell type segments, the Mammalian segment was the dominant segment in 2016 and is expected to retain its dominance through 2025. From an estimated US$ 216 Mn in 2017 to a market valuation in excess of US$ 680 Mn by the end of the forecast period, the Mammalian segment will register the highest CAGR of 15.6% among the other cell type segments. The Microbial segment is the second most attractive cell type segment in the global GMP cell banking services market in terms of revenue. Registering a value CAGR of 12.9% between 2017 and 2025, the Microbial segment will hold the second position among the cell type segments of the global GMP cell banking services market. Biopharmaceutical Companies will be the largest end users of GMP cell banking services Among the end user segment of the global GMP cell banking services market, the Biopharmaceutical Companies segment will emerge the undisputed leader both in terms of market share (estimated to hold almost 69% share by 2017 end) and CAGR (an impressive 15.4% during 2017 - 2025). In comparison, the Contract Manufacturing Organizations segment will come a pale second, recording a market attractiveness index of 0.5 during the forecast period. Request to View Report Table of Contents, Figures, and Tables @ http://www.persistencemarketresearch.com/market-research/gmp-cell-banking-service-market/toc The top companies profiled in the report include Wuxi AppTec, Charles River Laboratories International Inc, Eurofins Scientific, Merck KGaA, Lonza Group Ltd., SGS Ltd., ViruSure GmbH, Austrianova, Goodwin Biotechnology Inc., and Paragon Bioservices Inc. Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


News Article | July 20, 2017
Site: www.prnewswire.com

"We are building a world class team and Ms. Wild's experience and leadership is spot on to support Paragon's growth initiatives in GMP vaccine and viral vector manufacturing," stated Peter Buzy, President and CEO of Paragon.  "Having both quality and manufacturing experience, Deb has a strong track record of executing plans that have added the profitability for the companies she has been employed by, both as an employee and as a consultant.  We are excited to have Deborah join our senior team and to be a critical part of the Company's future growth.  We look forward to her contributions as we continue to grow the company." Ms. Wild is an accomplished Quality Executive/Leader with 30 years' experience.  Most recently she ran a thriving consulting practice, for over 14 years, leading Quality Assurance focused initiatives for high profile clients such as Genentech, TEVA, Polynoma, Cytovance, CMC Biologics, etc.  Managing her consulting on the side, Ms. Wild occupied full time roles at Polynoma as VP of Quality Systems and VP of Manufacturing and Supply Chain at Victory Pharma.  Prior to launching her practice, she spent over 17 years at Genentech ending there as Director of Contract Manufacturing.  Through her experience, Ms. Wild has earned a strong reputation for adding to company growth strategies by effectively transforming Quality organizations into strong business partners. Additionally, Ms. Wild was a member of our armed forces serving in the Army having been deployed to Desert Storm towards the end of her enlistment.  She began as a Private First Class and left having achieved the rank of Staff Sergeant. About Paragon Bioservices, Inc. Paragon Bioservices is a private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of biopharmaceuticals—including the production and purification of monoclonal antibodies, recombinant proteins, viral vectors and vaccines. The company provides research services, process development and cGMP manufacturing. Paragon's cGMP facilities include microbial and mammalian suites, fill-finish and fully-segregated virus facilities.


Miller M.S.,Monash Institute of Pharmaceutical Sciences | Miller M.S.,Johns Hopkins University | Schmidt-Kittler O.,Johns Hopkins University | Schmidt-Kittler O.,Sanofi S.A. | And 14 more authors.
Oncotarget | Year: 2014

We report two crystal structures of the wild-type phosphatidylinositol 3-kinase a (PI3Kα) heterodimer refined to 2.9 Å and 3.4 Å resolution: the first as the free enzyme, the second in complex with the lipid substrate, diC4-PIP2, respectively. The first structure shows key interactions of the N-terminal SH2 domain (nSH2) and iSH2 with the activation loop that suggest a mechanism by which the enzyme is inhibited in its basal state. In the second structure, the lipid substrate binds in a positively charged pocket adjacent to the ATP-binding site, bordered by the P-loop, the activation loop and the iSH2 domain. An additional lipid-binding site was identified at the interface of the ABD, iSH2 and kinase domains. The ability of PI3Kα to bind an additional PIP2 molecule was confirmed in vitro by fluorescence quenching experiments. The crystal structures reveal key differences in the way the nSH2 domain interacts with wild-type p110a and with the oncogenic mutant p110aH1047R. Increased buried surface area and two unique salt-bridges observed only in the wild-type structure suggest tighter inhibition in the wild-type PI3Kα than in the oncogenic mutant. These differences may be partially responsible for the increased basal lipid kinase activity and increased membrane binding of the oncogenic mutant.


PubMed | University of Turku, University of Maryland Baltimore County, Paragon Bioservices, Imperial College London and 2 more.
Type: Journal Article | Journal: PLoS pathogens | Year: 2014

Enteroaggregative Escherichia coli (EAEC) is a leading cause of acute and persistent diarrhea worldwide. A recently emerged Shiga-toxin-producing strain of EAEC resulted in significant mortality and morbidity due to progressive development of hemolytic-uremic syndrome. The attachment of EAEC to the human intestinal mucosa is mediated by aggregative adherence fimbria (AAF). Using X-ray crystallography and NMR structures, we present new atomic resolution insight into the structure of AAF variant I from the strain that caused the deadly outbreak in Germany in 2011, and AAF variant II from archetype strain 042, and propose a mechanism for AAF-mediated adhesion and biofilm formation. Our work shows that major subunits of AAF assemble into linear polymers by donor strand complementation where a single minor subunit is inserted at the tip of the polymer by accepting the donor strand from the terminal major subunit. Whereas the minor subunits of AAF have a distinct conserved structure, AAF major subunits display large structural differences, affecting the overall pilus architecture. These structures suggest a mechanism for AAF-mediated adhesion and biofilm formation. Binding experiments using wild type and mutant subunits (NMR and SPR) and bacteria (ELISA) revealed that despite the structural differences AAF recognize a common receptor, fibronectin, by employing clusters of basic residues at the junction between subunits in the pilus. We show that AAF-fibronectin attachment is based primarily on electrostatic interactions, a mechanism not reported previously for bacterial adhesion to biotic surfaces.


Matsumoto N.M.,University of California at Los Angeles | Buchman G.W.,Paragon Bioservices | Rome L.H.,University of California at Los Angeles | Maynard H.D.,University of California at Los Angeles
European Polymer Journal | Year: 2015

Abstract Multiply responsive protein nanoparticles are interesting for a variety of applications. Herein, we describe the synthesis of a vault nanoparticle that responds to both temperature and pH. Specifically, poly(N-isopropylacrylamide-co-acrylic acid) with a pyridyl disulfide end group was prepared by reversible addition-fragmentation chain transfer (RAFT) polymerization. The polymer had a lower critical solution temperature (LCST) of 31.9 °C at pH 5, 44.0 °C at pH 6 and above 60 °C at pH 7. The polymer was conjugated to human major vault protein (hMVP), and the resulting nanoparticle was analyzed by UV-Vis, dynamic light scattering (DLS) and electron microscopy. The data demonstrated that the poly(N-isopropylacrylamide-co-acrylic acid)-vault conjugate did not respond to temperatures below 60 °C at pH 7, while the nanoparticles reversibly aggregated at pH 6. Furthermore, it was shown that the vault nanoparticle structure remained intact for at least three heat and cooling cycles. Thus, these dually responsive nanoparticles may serve as a platform for drug delivery and other applications. © 2015 Elsevier Ltd.


PubMed | University of California at Los Angeles and Paragon Bioservices
Type: | Journal: European polymer journal | Year: 2015

Multiply responsive protein nanoparticles are interesting for a variety of applications. Herein, we describe the synthesis of a vault nanoparticle that responds to both temperature and pH. Specifically, poly(


BALTIMORE, Nov. 18, 2016 /PRNewswire/ -- Paragon Bioservices, Inc., a global leader in the manufacturing of biopharmaceuticals and vaccines, announced today the appointment of Ruby Hofmann to the position of Vice President, Human Resources and Organizational Development, where she will...


News Article | November 22, 2016
Site: www.prnewswire.com

BALTIMORE, Nov. 22, 2016 /PRNewswire/ --  A global leader in the manufacturing of biopharmaceuticals, vaccines, and viral vectors announced today the appointment of John Conner to the position of Senior Vice President of GMP Manufacturing. "We are building a world class GMP team to co...

Loading Paragon Bioservices collaborators
Loading Paragon Bioservices collaborators